MDMA for Borderline Personality Disorder
(MDMA in BPD Trial)

Recruiting in Palo Alto (17 mi)

Overseen bySarah K Fineberg, MD, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Yale University

No Placebo Group

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Eligibility Criteria

This trial is for adults with Borderline Personality Disorder. Specific eligibility criteria are not provided, but typically participants must meet diagnostic criteria for the condition being studied and may need to pass certain health checks.

Inclusion Criteria

Willing to remain overnight at the study site after each experimental session if recommended

Able to provide written informed consent according to Yale IRB guidelines

Able to read and write English proficiently

+11 more

Exclusion Criteria

History of bipolar disorder, schizophrenia, schizoaffective disorder, or currently exhibiting psychotic features

My heart often beats faster than 90 beats per minute.

I have a history of serious medical or neurological illness.

+10 more

Participant Groups

The study is testing the effects of MDMA on social cognition in individuals with Borderline Personality Disorder. Social cognition involves how people process, store, and apply information about others and social situations.

1Treatment groups

Experimental Treatment

Group I: Open-Label MDMAExperimental Treatment1 Intervention

Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

MDMA is already approved in United States for the following indications:

🇺🇸 Approved in United States as MDMA for: